Algert Global LLC Purchases New Shares in DexCom, Inc. $DXCM

Key Points

• Algert Global LLC acquired a new stake in DexCom, purchasing 5,860 shares valued at around $400,000 during the first quarter.
• Several analysts have raised their price targets for DexCom, with Morgan Stanley increasing it to $89 and Piper Sandler to $100, contributing to a consensus rating of "Moderate Buy" from the market.
• Insider trading activity showed that certain directors of DexCom sold shares, with a total of 21,906 shares valued at $1.8 million sold last quarter, decreasing some insiders' stakes in the company.

Algert Global LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,860 shares of the medical device company's stock, valued at approximately $400,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DXCM. Brighton Jones LLC lifted its position in DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its position in DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after acquiring an additional 2,010 shares during the last quarter. MML Investors Services LLC lifted its position in DexCom by 17.0% during the fourth quarter. MML Investors Services LLC now owns 36,235 shares of the medical device company's stock valued at $2,818,000 after acquiring an additional 5,260 shares during the last quarter. Stifel Financial Corp lifted its position in DexCom by 8.8% during the fourth quarter. Stifel Financial Corp now owns 101,013 shares of the medical device company's stock valued at $7,856,000 after acquiring an additional 8,142 shares during the last quarter. Finally, MGO One Seven LLC purchased a new stake in DexCom during the fourth quarter valued at approximately $412,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on DXCM shares. Mizuho increased their target price on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. UBS Group raised their price target on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. The Goldman Sachs Group began coverage on shares of DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Oppenheimer raised their price target on shares of DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, July 31st. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $106.00 price target on shares of DexCom in a report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $0.26 during midday trading on Friday, reaching $75.34. The company's stock had a trading volume of 2,921,932 shares, compared to its average volume of 4,186,415. The firm has a market capitalization of $29.54 billion, a PE ratio of 52.32, a P/E/G ratio of 1.58 and a beta of 1.43. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The stock has a fifty day moving average of $82.25 and a 200 day moving average of $79.44. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $88.99, for a total transaction of $130,459.34. Following the completion of the sale, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. The trade was a 1.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,722 shares of company stock worth $1,306,131 over the last ninety days. 0.32% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.